Genmab A/S (NASDAQ:GMAB) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock.

Several other research analysts also recently commented on the company. Royal Bank of Canada raised Genmab A/S from a sector perform rating to an outperform rating in a research note on Monday, July 15th. BTIG Research upped their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a buy rating in a research note on Thursday, June 27th. Finally, Truist Financial raised their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research note on Tuesday, June 4th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $49.50.

Genmab A/S Price Performance

Genmab A/S stock traded down $0.64 during midday trading on Friday, reaching $26.43. The company had a trading volume of 482,367 shares, compared to its average volume of 596,317. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $39.53. The firm’s fifty day simple moving average is $26.79 and its 200-day simple moving average is $28.22. The company has a market capitalization of $17.48 billion, a P/E ratio of 22.03, a P/E/G ratio of 1.01 and a beta of 0.97.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its position in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after acquiring an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Genmab A/S in the 1st quarter worth approximately $43,000. Principal Securities Inc. purchased a new position in shares of Genmab A/S during the 4th quarter worth approximately $77,000. Finally, Barometer Capital Management Inc. acquired a new stake in Genmab A/S in the 4th quarter valued at approximately $121,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.